{
  "ticker": "MRNA",
  "company_name": "Moderna, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05894590",
      "title": "Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19",
      "status": "COMPLETED",
      "phase": "",
      "condition": "SARS-CoV-2",
      "start_date": "2022-11-15",
      "completion_date": "2023-12-20",
      "enrollment": 0,
      "sponsor": "ModernaTX, Inc."
    },
    {
      "nct_id": "NCT03382405",
      "title": "Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Cytomegalovirus Infection",
      "start_date": "2017-11-13",
      "completion_date": "2020-10-28",
      "enrollment": 0,
      "sponsor": "ModernaTX, Inc."
    },
    {
      "nct_id": "NCT05330975",
      "title": "A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults \u226550 Years of Age",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Respiratory Syncytial Virus",
      "start_date": "2022-04-01",
      "completion_date": "2024-11-08",
      "enrollment": 0,
      "sponsor": "ModernaTX, Inc."
    },
    {
      "nct_id": "NCT05333289",
      "title": "A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Seasonal Influenza",
      "start_date": "2022-04-06",
      "completion_date": "2022-11-22",
      "enrollment": 0,
      "sponsor": "ModernaTX, Inc."
    },
    {
      "nct_id": "NCT05659264",
      "title": "A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Chronic Heart Failure",
      "start_date": "2022-12-05",
      "completion_date": "2024-12-17",
      "enrollment": 0,
      "sponsor": "ModernaTX, Inc."
    },
    {
      "nct_id": "NCT05398796",
      "title": "Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Nipah Virus Infection",
      "start_date": "2022-07-11",
      "completion_date": "2024-09-17",
      "enrollment": 0,
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)"
    },
    {
      "nct_id": "NCT06147856",
      "title": "A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria",
      "status": "WITHDRAWN",
      "phase": "PHASE1, PHASE2",
      "condition": "Phenylketonuria",
      "start_date": "2024-03-29",
      "completion_date": "2027-08-05",
      "enrollment": 0,
      "sponsor": "ModernaTX, Inc."
    },
    {
      "nct_id": "NCT06602024",
      "title": "A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults \u226550 Years of Age",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Seasonal Influenza",
      "start_date": "2024-09-16",
      "completion_date": "2025-08-21",
      "enrollment": 0,
      "sponsor": "ModernaTX, Inc."
    },
    {
      "nct_id": "NCT04144348",
      "title": "Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Human Metapneumovirus and Human Parainfluenza Infection",
      "start_date": "2019-11-04",
      "completion_date": "2022-12-20",
      "enrollment": 0,
      "sponsor": "ModernaTX, Inc."
    },
    {
      "nct_id": "NCT05933304",
      "title": "A Study of the Effectiveness of Moderna COVID-19 Vaccine",
      "status": "COMPLETED",
      "phase": "",
      "condition": "SARS-CoV-2, COVID-19",
      "start_date": "2020-12-18",
      "completion_date": "2023-11-17",
      "enrollment": 0,
      "sponsor": "ModernaTX, Inc."
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "": 8,
      "PHASE1": 15,
      "PHASE3": 12,
      "PHASE1, PHASE2": 7,
      "PHASE4": 3,
      "PHASE2, PHASE3": 1,
      "PHASE2": 4
    },
    "by_status": {
      "COMPLETED": 30,
      "WITHDRAWN": 2,
      "RECRUITING": 6,
      "ACTIVE_NOT_RECRUITING": 7,
      "TERMINATED": 4,
      "ENROLLING_BY_INVITATION": 1
    },
    "active_trials": 14,
    "completed_trials": 30,
    "conditions": [
      "Acute Gastroenteritis, Norovirus Acute Gastroenteritis",
      "Chronic Heart Failure",
      "Cutaneous Melanoma, Synovial Sarcoma",
      "Cytomegalovirus Infection",
      "Glycogen Storage Disease",
      "HIV Infections",
      "Healthy Participants",
      "Healthy Volunteers",
      "Human Metapneumovirus and Human Parainfluenza Infection",
      "Immunocompromised Patients",
      "Influenza",
      "Melanoma",
      "Methylmalonic Acidemia, Propionic Acidemia",
      "Multiple Myeloma",
      "Myocarditis",
      "Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms",
      "Nipah Virus Infection",
      "Norovirus Acute Gastroenteritis",
      "Phenylketonuria",
      "Relapsed or Refractory Multiple Myeloma",
      "Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer",
      "Respiratory Syncytial Virus",
      "SARS-CoV-2",
      "SARS-CoV-2, COVID-19",
      "SARS-CoV-2, Influenza",
      "Seasonal Influenza",
      "Zika Virus"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:20:06.648150",
    "search_query": "Moderna, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Moderna,+Inc."
  }
}